• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Polyrizon Ltd.

    5/1/25 5:01:11 PM ET
    $PLRZ
    Get the next $PLRZ alert in real time by email
    6-K 1 ea0240537-6k_polyrizon.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of May 2025

     

    Commission file number: 001-42375

     

    Polyrizon Ltd.

    (Translation of registrant’s name into English)

     

    5 Ha-Tidhar Street

    Raanana, 4366507, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

    CONTENTS

     

    Polyrizon Ltd. (the “Company”) is announcing that the planned reverse share split of the Company’s ordinary shares at the ratio of 1-for-10 that was previously announced on May 1, 2025, will not be effectuated.

     

    This Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statement on Form S-8 (File No. 333-284410), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Polyrizon Ltd.
       
    Date: May 1, 2025 By: /s/ Tomer Izraeli
      Name:  Tomer Izraeli
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $PLRZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLRZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLRZ
    SEC Filings

    See more
    • SEC Form 6-K filed by Polyrizon Ltd.

      6-K - Polyrizon Ltd. (0001893645) (Filer)

      5/22/25 9:27:03 AM ET
      $PLRZ
    • SEC Form 6-K filed by Polyrizon Ltd.

      6-K - Polyrizon Ltd. (0001893645) (Filer)

      5/21/25 7:25:11 AM ET
      $PLRZ
    • SEC Form 6-K filed by Polyrizon Ltd.

      6-K - Polyrizon Ltd. (0001893645) (Filer)

      5/19/25 8:30:21 AM ET
      $PLRZ

    $PLRZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

      The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform. The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, utilizing excised rabbit nasal mucosa as a surrogate for human nasal tissues. The research aimed to characterize two ke

      5/21/25 7:10:00 AM ET
      $PLRZ
    • Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

      Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse

      5/13/25 7:45:00 AM ET
      $PLRZ
    • Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

      Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product's development path.  Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated strong local tolerability, a critical benchmark in the product development roadmap. The study was designed to assess local tolerance and tissue response following a 4-hour application of a formulation

      4/25/25 7:37:00 AM ET
      $PLRZ

    $PLRZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

      Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

      12/19/24 7:22:00 AM ET
      $PLRZ
    • Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

      Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

      12/13/24 6:25:00 AM ET
      $PLRZ